Serum Institute of India gets DCGI nod to conduct Phase 2, 3 human clinical trials of Oxford vaccine candidate


Content Team
Image Credit: Shortpedia

In a major development in India's fight against the novel coronavirus, the Drugs Controller General of India (DCGI) has permitted the Serum Institute of India to conduct phase 2 and 3 human clinical trials of the Oxford University developed COVID-19 vaccine candidate in the country. "The firm has to submit safety data, evaluated by the DSMB, to the CDSCO before proceeding to phase 3 clinical trials," a senior official said.